Product Code: RND-25
From £445.00
Registration closed: 30/11/2024
Applicable to labs that undertake NGS-based testing for this group of disorders (including targeted panel testing/ virtual panel /clinical exome / WES / WGS)
CNV, MLPA, NGS, Panel testing, Whole exome sequencing, Whole genome sequencing
English
DNA (in TE Buffer)
Yes
The scheme
is designed to assess the entire diagnostic pipeline of a laboratory, including
sample receipt and processing, analytical processing (genotyping), and
reporting (biological and clinical interpretation of the test result) in the
context of a clinical referral, as well as reporting clarity, content and
clerical accuracy.
Three mock clinical cases with matching samples will be provided
Approximately 2µg DNA per sample is provided. Complete information will be available in scheme instructions.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply*)
*Sanctions, delivery network exceptions, restrictions on importation etc.
Collaboration with European Reference Network for Rare Neurological Diseases (ERN-RND) – see website for more information.
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.